Dr. Swerdloff on promising results with oral testosterone undecanoate

“The difference between this compound and other compounds that were orally administered, is that this seems to go through the lymphatic system rather than going directly to the liver,” says Ronald Swerdloff, MD.

In this video, Ronald Swerdloff, MD, discusses the background and findings of the study, “Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Swerdloff is a professor of medicine and senior investigator at The Lundquist Institute, Harbor-UCLA Medical Center and David Geffen School of Medicine, University of California, Los Angeles.